LDN for Anxiety: What We Know and Who It May Help

Low-dose naltrexone, often called LDN, is getting more attention in mental health care. At the same time, it is not a standard first-line treatment for anxiety, so it helps to keep expectations grounded.

As psychiatric nurse practitioners, we use a whole-person lens. We look at anxiety symptoms, stress load, sleep, inflammation, physical health, and daily habits, not medication alone. That matters because anxiety rarely comes from one source. The goal here is to explain what LDN is, how it may help some people, who may be a good fit, and what safe treatment usually looks like in real life.

How LDN may fit into a whole-person plan for anxiety

Anxiety can feel mental such as excessive worry, overthinking, and racing thoughts, but many people notice it in the body first. Their chest tightens, sleep breaks apart, pain rises, and their stress system stays on high alert. In cases like that, we sometimes consider treatments that reach beyond the usual anxiety pathways.

LDN is an off-label option, and it should be guided by a licensed clinician.

What low-dose naltrexone is, and why people are talking about it

Naltrexone has been around for years. At its standard dose, usually 50 mg, it is used for opioid or alcohol use disorders. LDN uses the same medication in a much smaller amount, often around 0.5 mg to 4.5 mg. Because the dose is so low, the effect may be different from full-dose naltrexone.

Interest in LDN comes from a few areas. Some clinicians use it when patients have chronic pain, autoimmune symptoms, fatigue, or poor sleep along with anxiety. The theory is that low doses may affect inflammation, immune signaling, endorphins, and pain processing. Those systems can shape how wired or worn down a person feels.

That said, LDN is usually a support tool, not a cure. We don't frame it as a magic fix. We see it as one option that may fit into whole-person anxiety care when the clinical picture points in that direction.

Why a whole-person approach matters when anxiety has more than one cause

We rarely see anxiety in a vacuum. It may be tied to trauma, burnout, hormone shifts, gut symptoms, chronic illness, substance use, or sleep loss. Sometimes the body looks inflamed and exhausted. Other times, the main driver is panic, grief, or a mood disorder that hasn't been treated well.

Because of that, we don't jump to LDN just because someone feels anxious. We look at the full picture first. If anxiety overlaps with pain, immune symptoms, restless sleep, or medication sensitivity, LDN may come up in the conversation. If the pattern points somewhere else, we choose a different path.

What the research says about LDN for anxiety, and where the limits are

The research on LDN and anxiety is still thin. We do not have strong, large clinical trials showing that it works as a primary anxiety treatment across the board. That is the honest starting point.

Most of the interest comes from related conditions where anxiety often rides along, such as fibromyalgia, chronic pain, autoimmune illness, long-term inflammation, and sleep disruption. Those links are worth watching.

What we know so far from related conditions and real-world use

When LDN helps, it may help indirectly. For example, if a person's pain eases, sleep improves, and their stress response settles, anxiety may come down too. That can be meaningful, especially for people stuck in a loop where pain worsens sleep, sleep worsens stress, and stress worsens anxiety.

We also hear encouraging reports from patients and clinicians. Some people say they feel less activated, less achy, or more resilient after a careful trial.

If you want more background on that overlap, this piece on how low-dose naltrexone may affect anxiety and sleep gives added context.

Why LDN is not a one-size-fits-all anxiety treatment

Anxiety has many drivers. A person with panic disorder may need a different plan than someone whose anxiety rises with autoimmune flares. Severe trauma symptoms, stimulant overuse, OCD-type intrusive thoughts, or an untreated bipolar-spectrum condition call for careful assessment first.

In those cases, LDN may not address the main problem. The better move may be therapy, sleep treatment, substance use support, medication changes, or trauma-focused care. For people dealing with repetitive fear loops, care for intrusive thoughts and anxiety often points toward treatments like CBT or ERP instead.

This is where individualized care matters. We match the treatment to the pattern, not the trend.

Who may be a good candidate for LDN, and who needs extra caution

LDN usually enters the picture when anxiety is mixed with body-based symptoms. That might mean chronic pain, frequent inflammation, autoimmune issues, restless sleep, or a system that seems overly reactive to stress. It can also come up when someone is sensitive to standard medications and wants a careful, measured plan.

Signs LDN may be worth discussing with a psychiatric provider

We may talk about LDN when someone describes patterns like these:

• Anxiety that flares with pain, poor sleep, or immune symptoms.

• Feeling run down, tense, and physically stressed for long stretches.

• Medication sensitivity, especially when standard options like SSRIs feel hard to tolerate.

• A cycle where fatigue, pain, and worry keep feeding each other.

This is only a conversation starter. It is not a self-diagnosis checklist. The same symptoms can come from many causes, so we still need a full history before we decide whether LDN makes sense.

When LDN may not be the right choice

The clearest caution is current opioid use. Naltrexone can block opioid receptors, so combining it with opioid pain medicine can cause serious problems. Anyone using opioids, even on and off, needs careful review before LDN is considered.

We also review pregnancy or breastfeeding status, liver history, current supplements, and the full medication list. Timing matters too. Some people do better taking LDN at night, while others need a morning dose if sleep gets disrupted. Dose matters as well, because starting too high can make a sensitive person feel worse.

Caution is not the same as fear. It simply means this medication deserves thoughtful screening.

What treatment with LDN can look like in real life

A careful LDN trial usually starts low and moves slowly. We often begin with a small dose, then adjust based on sleep, side effects, anxiety patterns, pain, energy, and daily function. That slow pace helps us tell the difference between a true benefit and a rough start.

Common side effects, expected timeline, and dosing basics

Some people notice vivid dreams, nausea, headache, stomach upset, or sleep changes. Others notice nothing at first. A few feel more alert for a while and need a dose change. Some people do not benefit at all, and that matters too.

If LDN helps, the shift may take time. We usually look for gradual changes, not overnight relief. That might mean less pain reactivity, steadier sleep, lower body tension, or fewer days spent in a stressed-out fog. Those changes can support anxiety treatment.

Because low doses are often customized, clinicians may use a compounded form. That is another reason we want clear follow-up.

What we combine with LDN to support better anxiety care

When we prescribe LDN, we pair it with other supports that fit the person in front of us. That may include therapy, sleep work, nutrition changes, movement, stress-reduction habits, lab review when needed, and nervous system skills. For many people, small daily shifts matter as much as the prescription.

We also like practical tools that help in the moment. These DBT skills for anxiety regulation can support people while the broader plan takes shape.

A good care plan should make life more workable, not more complicated. If LDN is part of that plan, it should fit alongside the basics that help the brain and body settle.

Final thoughts

LDN may be a reasonable option for some people with anxiety, especially when anxiety overlaps with pain, inflammation, poor sleep, or other whole-body concerns. Still, it is not standard first-line care, and it is not right for everyone.

The strongest takeaway is simple: anxiety treatment should be personal. We get the best results when we look at the full person, screen carefully, and choose treatments that match the real pattern underneath the symptoms.

If LDN is on your radar, a careful conversation with a qualified psychiatric clinician is the right next step. That is how we build care plans that are grounded, safe, and more likely to help.

Content on this website is not considered medical advice and does not establish a patient provider relationship. Please consult with a licensed health care provider before making any medical or lifestyle changes.

References:

Abhinav Choubey, et al. “Low-Dose Naltrexone Rescues Inflammation and Insulin Resistance Associated with Hyperinsulinemia.” Journal of Biological Chemistry, vol. 295, no. 48, 1 Nov. 2020, pp. 16359–16369, https://doi.org/10.1074/jbc.ra120.013484.

“Emory Researchers Call for an Inflammatory Subtype of Major Depression, Paving the Way for Precision Psychiatry | Emory University | Atlanta GA.” Emory.edu, 2025, news.emory.edu/stories/2025/06/hs_bhc_inflammatory_subtype_depression/story.html. Accessed 5 Mar. 2026.

Lee, Chieh-Hsin, and Fabrizio Giuliani. “The Role of Inflammation in Depression and Fatigue.” Frontiers in Immunology, vol. 10, no. 1696, 19 July 2019, https://doi.org/10.3389/fimmu.2019.01696.

LOTRICH, F. E., et al. “The Role of Inflammation in the Pathophysiology of Depression: Different Treatments and Their Effects.” The Journal of Rheumatology Supplement, vol. 88, no. 0, 1 Nov. 2011, pp. 48–54, www.jrheum.org/content/88/48.abstract, https://doi.org/10.3899/jrheum.110903.

Milaneschi, Yuri, et al. “Association of Inflammation with Depression and Anxiety: Evidence for Symptom-Specificity and Potential Causality from UK Biobank and NESDA Cohorts.” Molecular Psychiatry, vol. 26, no. 12, 16 June 2021, https://doi.org/10.1038/s41380-021-01188-w.

Weitzer, Danielle. “Chronic Fatigue Syndrome: Naltrexone as an Alternative Treatment.” MedCentral, MC, 26 May 2020, www.medcentral.com/pain/alternative-therapies/chronic-fatigue-syndrome-naltrexone-alternative-treatment. Accessed 5 Mar. 2026.

Yin, Yishu, et al. ““Inflamed” Depression: A Review of the Interactions between Depression and Inflammation and Current Anti-Inflammatory Strategies for Depression.” Pharmacological Research, vol. 207, 20 July 2024, pp. 107322–107322, https://doi.org/10.1016/j.phrs.2024.107322.

Younger, Jarred, et al. “The Use of Low-Dose Naltrexone (LDN) as a Novel Anti-Inflammatory Treatment for Chronic Pain.” Clinical Rheumatology, vol. 33, no. 4, 15 Feb. 2014, pp. 451–459, www.ncbi.nlm.nih.gov/pmc/articles/PMC3962576/pdf/10067_2014_Article_2517.pdf, https://doi.org/10.1007/s10067-014-2517-2.